Please assess the completion status of the following clinical trial:

Trial Title: Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
INCLUSION CRITERIA:~* Must have relapsed or refractory precursor B-cell acute lymphoblastic leukemia or acute lymphoblastic lymphoma.~* Participants with leukemia must meet one of the following:~  1. In first hematologic relapse, defined as the reappearance (in a patient who has previously achieved remission) of leukemia blasts in the bone marrow or peripheral blood, OR~ 2. Refractory to one or two courses of frontline induction therapy (≥ 5% blasts in the bone marrow or peripheral blood confirmed by flow cytometric analysis).~* Participant with lymphoma must meet one of the following:~  1. In first relapse, OR~ 2. Refractory to one or two courses of frontline induction therapy with measurable disease~     * Should flow cytometric analyses suggest relapse (by the reappearance of a similar immunophenotype to the original leukemia) in the presence of \<5% blasts morphologically, a repeat bone marrow test is recommended to confirm relapse.~    * Molecular or genetic relapse is characterized by the reappearance of a cytogenetic or molecular abnormality.~    * Early relapse is defined as relapse on therapy or \< 6 months after completion of frontline therapy. Late relapse is defined as relapse occurring ≥ 6 months after completion of frontline therapy.~* Participant's age is \< 22 years at time of enrollment (e.g. participant is eligible until 22nd birthday).~* Prior therapy:~  1. There is no waiting period for participants who relapse while receiving frontline therapy and are free from side effects attributable to such therapy.~ 2. Emergent radiation therapy, one dose of intrathecal chemotherapy, and up to 7 days of steroids for treatment of relapse are permitted before start of treatment in participants who relapse after completion of frontline therapy.~ 3. At least 90 days have elapsed since bone marrow transplant and participant is off immune suppression for a minimum of 2 weeks, if applicable. Participants with ALL or NHL who were transplanted in first remission are eligible for this study.~Organ function requirements~* Hepatic: Total bilirubin ≤ upper limit of normal (ULN) for age, or if total bilirubin is \> ULN, direct bilirubin ≤ 1.4 mg/dl~* Cardiac: Shortening fraction ≥ 28%~* Renal: Glomerular filtration rate \>50cc/min/1.73 m\^2, OR maximum serum creatinine (SC) based on age as follows:~  * If age is 1 to 2 years, then maximum SC is 0.6 mg/dL~ * If age is 2 to 6 years, then maximum SC is 0.8 mg/dL~ * If age is 6 to 10 years, then maximum SC is 1 mg/dL~ * If age is 10 to \<13 years, then maximum SC is 1.2 mg/dL~ * If age is 13 to 16 years, then maximum SC is 1.5 mg/dL for males and 1.4 mg/dL for females~ * If age is \>16 years, then maximum SC is 1.7 mg/dL for males and 1.4 mg/dL for females~EXCLUSION CRITERIA:~* Leukemia participants ages 1 to 5 years with induction failure AND favorable cytogenetics (i.e., hyperdiploidy defined as DNA index ≥1.16 or modal chromosome number ≥51, or ETV6-RUNXI).~* Hepatitis B or HIV infection.~* Pregnant or breast-feeding~* Inability or unwillingness or research participant or legal guardian/representative to give written informed consent.~INCLUSION CRITERIA FOR NK CELL DONORS:~* Donor is at least 18 years of age.~* Donor is a family member.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Standard Risk (Type: ACTIVE_COMPARATOR): Interventions: dexamethasone, vincristine sulfate, rituximab, clofarabine, cyclophosphamide, etoposide, aldesleukin, pegaspargase, methotrexate, mercaptopurine, cytarabine, mitoxantrone, teniposide, vinblastine, natural killer cell infusion, laboratory biomarker analysis, therapeutic hydrocortisone~Cells for infusion are prepared using the CliniMACS System.
- High Risk (Type: ACTIVE_COMPARATOR): Interventions: dexamethasone, vincristine, rituximab, clofarabine, cyclophosphamide, etoposide, aldesleukin, pegaspargase, methotrexate, mercaptopurine, cytarabine, mitoxantrone, natural killer cell infusion, allogeneic hematopoietic stem cell transplantation, laboratory biomarker analysis, therapeutic hydrocortisone~Cells for infusion are prepared using the CliniMACS System.

Based on this trial design, predict the completion outcome and termination type (if applicable).